Where hyaluronic acid is permitted, and what the file must show
Food-grade sodium hyaluronate is a supplement ingredient in the EU, the US and the UK, but permission is not one switch. The source route, the novel-food position, the contaminant ceilings, the label and the claim are five separate checks that the file must answer for the destination.
The source route, the novel-food position, the contaminant ceiling, the label and the claim are five separate checks, and each market answers them in its own instrument.
Five checks, one file
The checks are not interchangeable. A lot can meet a contaminant limit and still carry a forbidden label; a product can be lawful in one market and not another because the source or novel-food history differs. The operator placing the supplement on the market owns the assessment; the certificate is evidence, not a substitute. This is a sourcing reference, not legal advice.
European Union
Directive 2002/46/EC harmonises food supplements and sets a positive list of vitamins and minerals and their permitted forms. Sodium hyaluronate is neither, so Annex II does not apply; it falls under general food law and the supplement labelling particulars, and the operator must still show the ingredient is safe and lawfully used.
The novel-food question turns on the source and the process. In a 2023 Article 4 consultation under Regulation (EU) 2015/2283, sodium hyaluronate produced by fermentation with a non-genetically modified Streptococcus equi subsp. zooepidemicus strain was determined not to be a novel food for food supplements. The conclusion is specific to that process and use; another strain or route needs its own check. Animal tissue is separate: rooster comb extract has its own authorisation under Commission Implementing Decision 2013/705/EU, with a 60–80% hyaluronic acid specification.
Contaminants are governed by Regulation (EU) 2023/915. For food supplements, the ceilings are lead 3.0 mg/kg, cadmium 1.0 mg/kg and mercury 0.10 mg/kg. There is no harmonised EU maximum for arsenic, so that limit is buyer-set. Labelling follows Regulation (EU) No 1169/2011 and the supplement particulars; claims follow Regulation (EC) No 1924/2006, and as of this review the EU register has no authorised claim for sodium hyaluronate.
United States
In the US, sodium hyaluronate is sold in dietary supplements under DSHEA. FDA does not approve supplements or ingredients before sale, but the product must be made under the dietary supplement cGMP in 21 CFR 111, carry a Supplement Facts panel and meet the adverse-event reporting rules. An NDI notification, or another documented basis, belongs in the file.
The DSHEA drug-exclusion question deserves its own line. Hyaluronic acid has an FDA-approved drug history, and an article first approved as a drug is excluded from the dietary ingredient definition unless it was marketed as a supplement before that approval. The brand’s regulatory team should document the route it relies on; a GRAS conclusion for a food use does not settle the supplement route.
Structure/function claims are allowed if truthful, not misleading, substantiated and accompanied by the disclaimer. A claim that names a disease is a drug claim and is not allowed. California’s Proposition 65 adds its own lead threshold, so a product that meets the federal framework can still need a warning.
United Kingdom
Great Britain has its own novel-food regime, and the 2023 EU determination is not an automatic GB decision. The FSA register should be checked for the specific source and process. Northern Ireland applies EU novel-food rules under the Windsor Framework, so the two UK markets can answer differently.
Food supplements in England are governed by the Food Supplements (England) Regulations 2003, with equivalents in Scotland, Wales and Northern Ireland. Labelling follows assimilated food information rules; contaminants and claims follow retained GB law. As of this review, there is no authorised GB claim for sodium hyaluronate, and the GB contaminant ceilings should be checked in the current text.
The contaminant and source limits
| Check | EU | US | UK |
|---|---|---|---|
| Lead | 3.0 mg/kg | No federal limit; state law may apply | 3.0 mg/kg in GB limits; check text |
| Cadmium | 1.0 mg/kg | No federal supplement limit | 1.0 mg/kg in GB limits; check text |
| Mercury | 0.10 mg/kg | No federal supplement limit | 0.10 mg/kg in GB limits; check text |
| Arsenic | No harmonised limit; buyer specification | No federal limit | No harmonised limit; buyer specification |
| Microbiology | Buyer specification; HACCP-based controls | cGMP; buyer specification | Buyer specification; food safety controls |
| Source and novel food | Fermentation determination; animal route separate | DSHEA basis and drug-exclusion check | FSA register; NI follows EU |
The catalog limits are Pb ≤3, As ≤2, Cd ≤1 and Hg ≤0.1 mg/kg. Those figures sit at or inside the EU and GB ceilings for lead, cadmium and mercury; the arsenic line is buyer-set. A certificate that reports only “conforms” does not let the buyer compare the lot with the regulation; ask for individual results.
Where the claim boundary sits
No market allows a claim that names a disease or its course. The EU and UK allow only claims on the authorised register, which has no sodium hyaluronate entry as of this review. The US allows a structure/function claim with the disclaimer if it is truthful and substantiated, but not a disease claim. A statement about a body system is still a claim.
The label should describe the ingredient, the amount per portion and the source. It should not borrow a claim from another ingredient or market; a wording acceptable in the US is not automatically acceptable in the EU. This page makes no health claim.
The document pack
| Document | What it shows | When it is needed |
|---|---|---|
| Batch COA | Assay, glucuronic acid, molecular weight, moisture, contaminants, micro | Every lot |
| Specification / TDS | The release ranges and the methods | Every supplier qualification |
| Source and route statement | Fermentation or animal tissue; production organism or tissue | Every lot, all markets |
| Novel-food determination | The Article 4 conclusion or authorisation for the route | EU and UK files |
| Contaminant results | Individual lead, arsenic, cadmium and mercury figures | Every lot |
| Microbiology results | APC, yeast and mould, E. coli and Salmonella | Every lot |
| Label artwork and claim file | Ingredient name, amount, source and claim support | Before the first print run |
| GMP or HACCP certificate | The manufacturing control system | Supplier qualification; audit |
| Certificate of origin | Country of manufacture and export | Import and customs |
Before the first shipment
- Name the source route on the COA, TDS and label; “hyaluronic acid” cannot stand for either route.
- Record the novel-food position for the destination: EU determination, GB register or NI route.
- Compare individual heavy-metal results with the market ceiling, not only with “conforms”.
- Check the ingredient name and the amount per portion against the destination label rules.
- Check the claim wording against the EU/UK register or the US structure/function rules.
- Confirm the US dietary-ingredient basis and the drug-exclusion question with the brand’s regulatory team.
- Keep a retained sample tied by lot code to the certificate and the drum.
The market notes are on the EU, US and UK regulatory pages. Batch lines are explained on the COA page, source and identity on the identity page, and pack and lead time on the ordering page. The catalog specification is on the product page.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation